Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer.
Cetuximab is a monoclonal antibody that specifically blocks the epidermal growth factor receptor pathway. Cetuximab is now a standard drug to treat refractory advanced colorectal cancer. The most common side effect is a rash, seen in most patients. Ocular toxicity is uncommon. We report 2 cases of ocular toxicity characterized by blepharitis and conjunctivitis related to cetuximab administration. Strategies for management are discussed.